Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SHARPIN is a novel gene of colorectal cancer that promotes tumor growth potentially via inhibition of p53 expression.
Nakano Y, Masuda T, Sakamoto T, Tanaka N, Tobo T, Hashimoto M, Tatsumi T, Saito H, Takahashi J, Koike K, Abe T, Ando Y, Ozato Y, Hosoda K, Hirose K, Higuchi S, Ikehara T, Hisamatsu Y, Toshima T, Yonemura Y, Ogino T, Uemura M, Eguchi H, Doki Y, Mimori K. Nakano Y, et al. Among authors: hashimoto m. Int J Oncol. 2024 Dec;65(6):113. doi: 10.3892/ijo.2024.5701. Epub 2024 Oct 25. Int J Oncol. 2024. PMID: 39450547
Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
Hashimoto M, Masuda T, Nakano Y, Tobo T, Saito H, Koike K, Takahashi J, Abe T, Ando Y, Ozato Y, Hosoda K, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Hata T, Uemura M, Eguchi H, Doki Y, Mori M, Mimori K. Hashimoto M, et al. Cancer Sci. 2024 Jun;115(6):1866-1880. doi: 10.1111/cas.16129. Epub 2024 Mar 17. Cancer Sci. 2024. PMID: 38494600 Free PMC article.
Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.
Nakano T, Takao S, Dairaku K, Uno N, Low SA, Hashimoto M, Tsuda Y, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Eto K, Ikegami T, Fukunaga Y, Niida A, Nagayama S, Mimori K. Nakano T, et al. Among authors: hashimoto m. Cancer Sci. 2024 Jun;115(6):1989-2001. doi: 10.1111/cas.16149. Epub 2024 Mar 26. Cancer Sci. 2024. PMID: 38531808 Free PMC article.
Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis.
Hashimoto M, Kojima Y, Sakamoto T, Ozato Y, Nakano Y, Abe T, Hosoda K, Saito H, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Masuda T, Hata T, Nagayama S, Kagawa K, Goto Y, Utou M, Gamachi A, Imamura K, Kuze Y, Zenkoh J, Suzuki A, Takahashi K, Niida A, Hirose H, Hayashi S, Koseki J, Fukuchi S, Murakami K, Yoshizumi T, Kadomatsu K, Tobo T, Oda Y, Uemura M, Eguchi H, Doki Y, Mori M, Oshima M, Shibata T, Suzuki Y, Shimamura T, Mimori K. Hashimoto M, et al. EBioMedicine. 2024 May;103:105102. doi: 10.1016/j.ebiom.2024.105102. Epub 2024 Apr 12. EBioMedicine. 2024. PMID: 38614865 Free PMC article.
Comparative effects of biological and targeted synthetic DMARDs on incident chronic kidney disease in patients with rheumatoid arthritis.
Nishimura N, Onishi A, Yamamoto W, Nagai K, Shiba H, Okita Y, Son Y, Amuro H, Okano T, Ueda Y, Hara R, Katayama M, Yamada S, Hashimoto M, Maeda Y, Onizawa H, Fujii T, Murata K, Murakami K, Tanaka M, Matsuda S, Morinobu A. Nishimura N, et al. Among authors: hashimoto m. Rheumatology (Oxford). 2024 Oct 30:keae603. doi: 10.1093/rheumatology/keae603. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39475445
4,671 results